Ontario Teachers Pension Plan Board Lowers Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Ontario Teachers Pension Plan Board cut its position in Hologic, Inc. (NASDAQ:HOLX) by 62.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,637 shares of the medical equipment provider’s stock after selling 35,343 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Hologic were worth $1,763,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in shares of Hologic during the second quarter worth $25,000. Wolff Wiese Magana LLC purchased a new stake in Hologic in the third quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new position in shares of Hologic during the first quarter worth about $37,000. Sunbelt Securities Inc. purchased a new stake in shares of Hologic during the second quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Mizuho cut their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. UBS Group increased their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.91.

Hologic Stock Down 0.7 %

NASDAQ HOLX opened at $78.04 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The business has a 50 day moving average price of $80.52 and a two-hundred day moving average price of $78.30. The stock has a market cap of $18.13 billion, a PE ratio of 23.44, a P/E/G ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the previous year, the business earned $0.89 EPS. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, sell-side analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.